.Merck trumps revenues desires, brings up sales overview on solid demand for best medicines like Keytruda CNBCMerck & Co. (MRK US) Defeats Profit Projections as Keytruda Purchases Rise BloombergMerck Stock: Pharma Titan Posts Solid Outcomes, However Outlook Falls Short Client's Company DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck defeats revenue and sales requirements in the middle of Keytruda asset, but delivers combined full-year outlook MarketWatch.